Interaction Checker

Interaksi Sunitinib

Sunitinib (Sutent) memiliki 271 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 3 mayor, 267 moderat, 1 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (3)

  • BevasizumabMayor

    Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (label Sunitinib, Peringatan dan perhatian)

  • Itrakonazolantijamur azolMayor

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole. (label Vorikonazol, Interaksi obat)

Interaksi moderat (267)

  • AdenosinantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • AkarbosaantidiabetesModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • AlendronatbisfosfonatModerat

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (label Sunitinib, Peringatan dan perhatian)

  • Alfuzosinpenyekat alfaModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • AliskirenantihipertensiModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • AmiodaronantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Amitriptilinantidepresan trisiklikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Armodafinilstimulan SSPModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Arsen trioksidaobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Asam etakrinatdiuretik loopModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Asam zoledronatbisfosfonatModerat

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (label Sunitinib, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • AsenapinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • AtazanavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Beksagliflozinpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Bosentanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • DarunavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Darunavir dan kobisistatantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Deferasirokssuplemen zat besiModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • DeksametasonkortikosteroidModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Deutetrabenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Digoksinglikosida digitalisModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Diltiazempenghambat kanal kalsiumModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • DisopiramidantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • DofetilidantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Doksazosinpenyekat alfaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • DronedaronantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Droperidolantagonis dopaminModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Dulaglutidagonis reseptor GLP-1Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • EfavirenzantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Enalaprilatpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Eritromisinantibiotik makrolidaModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • EsitalopramSSRIModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • EslikarbazepinantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Esmololpenyekat betaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • EtravirinantiretroviralModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • EverolimusimunosupresanModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • FenitoinantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • FenobarbitalbarbituratModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Fenoksibenzaminpenyekat alfaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Fentermin dan topiramatstimulan SSPModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • FingolimodimunosupresanModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • FlekainidantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • FosamprenavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Fosaprepitantpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • FosfenitoinantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Fosinoprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • GlibenklamidsulfonilureaModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • GlimepiridsulfonilureaModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • GlipizidsulfonilureaModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • GriseofulvinantijamurModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Guanfasinagonis alfa-adrenergikModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • HidralazinvasodilatorModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • HidroksizinantihistaminModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • IbandronatbisfosfonatModerat

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (label Sunitinib, Peringatan dan perhatian)

  • IbutilidantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • IloperidonantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Insulin aspartinsulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Insulin degludekinsulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Insulin detemirinsulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Insulin glargininsulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Insulin lisproinsulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • IsoniazidantibiotikModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Isosorbid dinitrat dan hidralazinnitratModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Ivakaftorpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • KarbamazepinantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Karvedilolpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Ketokonazolantijamur azolModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Klaritromisinantibiotik makrolidaModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • KlobazambenzodiazepinModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Klonidinagonis alfa-adrenergikModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • KlorokuinantimalariaModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Klorotiaziddiuretik tiazidModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • KlorpromazinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Klortalidondiuretik tiazidModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • KlozapinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • KuetiapinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Kuinaprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • KuinidinantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • KuininantimalariaModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • LenakapavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • LevofloksasinfluorokuinolonModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • Lidokainanestetik lokalModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Lidokain dan prilokainanestetik lokalModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Lofeksidinagonis alfa-adrenergikModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Loperamidobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Lorlatinibpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • MeksiletinantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • MetadonopioidModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • MetforminbiguanidModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • MetildopaantihipertensiModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Metolazondiuretik tiazidModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • MiglitolantidiabetesModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • MinoksidilvasodilatorModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Mirabegronagonis beta-adrenergikModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Mitapivatpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Modafinilstimulan SSPModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Moeksiprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • MoksifloksasinfluorokuinolonModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Nadololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Nafsilinantibiotik penisilinModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • NateglinidmeglitinidModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • NefazodonantidepresanModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • NevirapinantiretroviralModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Nilotinibobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • NitroprusidvasodilatorModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • OkskarbazepinantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Ondansetronobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • PaliperidonantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • PamidronatbisfosfonatModerat

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (label Sunitinib, Peringatan dan perhatian)

  • Pentamidinobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • PerampanelantikonvulsanModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Perindoprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • PimavanserinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • PimozidantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Pindololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • PioglitazontiazolidindionModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Pitolisantobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Posakonazolantijamur azolModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Prazosinpenyekat alfaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • PrimidonantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • ProkainamidantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Prometazin dan dekstrometorfanantihistaminModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Prometazin dan kodeinopioidModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • PropafenonantiaritmiaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Ramiprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • RepaglinidmeglitinidModerat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • RifabutinantibiotikModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • RifampisinantibiotikModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • RifapentinantibiotikModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • RisedronatbisfosfonatModerat

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (label Sunitinib, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • RitonavirantiretroviralModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • SenobamatantikonvulsanModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Simetidinpenghambat H2Moderat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Sitagliptinpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • SitalopramSSRIModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • SolifenasinantikolinergikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Sotalolpenyekat betaModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • Suzetriginpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • TakrolimusimunosupresanModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Tamoksifenmodulator reseptor estrogen selektifModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TemsirolimusModerat

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (label Temsirolimus, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Teriparatidhormon tiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Tiamazolobat antitiroidModerat

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (label Sunitinib, Peringatan dan perhatian)

  • TikagrelorantiplateletModerat

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (label Sunitinib, Peringatan dan perhatian)

  • TioridazinantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Tirzepatidagonis reseptor GLP-1Moderat

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

  • Tizanidinpelemas ototModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TolterodinantikolinergikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • TopiramatantikonvulsanModerat

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (label Sunitinib, Interaksi obat)

  • Torasemiddiuretik loopModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • TramadolopioidModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Tramadol dan parasetamolopioidModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Trandolaprilpenghambat ACEModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TrazodonantidepresanModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Triamterendiuretik hemat kaliumModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Valbenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • VenlafaksinSNRIModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • ZiprasidonantipsikotikModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

Penyebutan minor (1)

  • AksitinibMinor

    MACE occurred in 7% of patients with advanced RCC treated with INLYTA in combination with avelumab compared to 3.4% treated with sunitinib in a randomized trial, JAVELIN Renal 101. (label Aksitinib, Peringatan dan perhatian)

Periksa Sunitinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.